Whole Body Vibration in Chronic Obstructive Pulmonary Disease

NCT ID: NCT01850173

Last Updated: 2013-05-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-28
• Study Completion Date: 2011-12-31

Brief Summary

The investigators designed the current study with the main objective of determining whether Whole Body Vibration Training (WBVT) alone improves muscular force and/or modifies the functional capacity parameters in severe Chronic Obstructive Pulmonary Disease (COPD) patients referred to a rehabilitation programme.

Conditions

COPD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

static work with a vertical vibration platform

The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.

Group Type: EXPERIMENTAL

A vertical vibration platform Fitybe

Intervention Type: DEVICE

They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.

Control group

general recommendations about physical activity and lifestyle

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

A vertical vibration platform Fitybe

They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• severe COPD defined as a post-bronchodilator forced expiratory volume at one second (FEV1)/ forced vital capacity (FVC) < 0.7 and FEV1 < 50% predicted,
• stable disease defined as no exacerbation,
• hospital admission or change in treatment in the previous 3 months.

Exclusion Criteria

• other significant respiratory disease (bronchiectasis,
• lung fibrosis, asthma, etc),
• active smoking,
• severe cardiovascular,
• neurological, and/or metabolic pathology that could interfere with the results,
• total hip, knee or ankle arthroplasty,
• previous vitreous haemorrhage,
• severe alcoholism (> 80 g/day) and
• severe malnutrition (BMI < 19 Kg/m2) to reduce the risk of falling and dropouts.

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Hospital de Mataró

OTHER

Sponsor Role: lead

Responsible Party

Eulogio Pleguezuelos

Doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Eulogio Pleguezuelos, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital de Mataró

Locations

Eulogio Pleguezuelos

Mataró, Barcelona, Spain

Countries

Spain

Related Links

http://www.csdm.cat

Hospital de Mataró. Consorci Sanitari del Maresme

Other Identifiers

MAT-VIB01

Identifier Type: -

Identifier Source: org_study_id